The crude drug aconite ("bushi" in Japanese) is derived from the roots of certain Aconitum species (Ranunculaceae), which are widely distributed both in China and Japan. The drug is highly toxic, but is frequently used as a component of many prescriptions used in traditional Chinese medicine, and has analgesic, anti-inflammatory, cardiovascular, and CNS activities as well as contractile effects on smooth and striated muscle. 1) Aconitine, an extremely toxic ingredient of aconite, 1,2) has pharmacological effects such as antinociceptive, 3) anti-inflammatory, 4) and positive inotropic 5,6) actions.
with a Fourier transfer (FT)/IR-230 spectrometer (Jasco Co., Tokyo). 1 H-and 13 C-NMR spectra were measured with a Varian Unitity 500 spectrometer or a Gemini 300 spectrometer, and chemical shifts are recorded in d values. Tetramethylsilane (TMS) was used as an internal standard. Electrospray ionization mass (ESI-MS) spectra were measured with a Perkin-Elmer SCIEX API III biomolecular mass analyzer. Analytical TLC was carried out on precoated Kiesel gel F 254 plates (0.25 mm, Merck) and the spots were detected either under UV light or after exposure to I 2 . Fluorometry was performed on a Shimadzu RF-5000 spectrofluorometer.
Synthesis of Two Hemiesters of Benzoylaconine 1) Collidine (0.12 ml) and succinic acid (1.05 mmol) were added to a solution (1.5 ml) of aconitine (0.046 mmol, 1) in tetahydrofuran (THF), and the mixture was heated at 70°C with stirring for 22 h. The reaction mixture was evaporated to dryness under reduced pressure and then purified by silica gel chromatography (CHCl 3 -MeOHϭ7 : 3) to give a colorless oily compound, succinic acid hemiester of benzoylaconine (2) (21.8 mg, 67.7% in yield from aconitine).
[a] D Ϫ1.4°(cϭ1.7, CHCl 3 ). IR n max : 3450 (OH), 1720 (CϭO), 1600, 1582, 1455 (Ph). 1 2) Collidine (0.05 ml) and hexadecanedioic acid (0.33 mmol) were added to 0.5 ml of THF containing 0.019 mmol aconitine, and the mixture was stirred for 5 h at 70°C. The reaction mixture was evaporated to dryness under reduced pressure, and then purified by silica gel chromatography (CHCl 3 -MeOHϭ8 : 2) to give a colorless oily compound, hexadecanedioic acid hemiesters of benzoylaconine (3) Preparation of BSA Conjugates (6, n‫;2؍‬ 7, n‫)41؍‬ Succinimidyl ester 4 (17.6 mmol) in 0.2 ml of pyridine was added to BSA (0.61 mmol) in 3 ml of phosphate buffer (pH 7.3). The mixture was stirred for 24 h at 4°C, and successively dialyzed for one week against 10%, 5%, 2.5% pyridine-H 2 O and H 2 O, and then lyophilized in vacuo to give a BSA conjugate Ig1 (6) . Similarly, succinimidyl ester 5 (6.7 mmol) in 0.2 ml pyridine and BSA (0.23 mmol) in 3 ml of phosphate buffer (pH 7.3) were incubated under the above conditions to give a BSA conjugate Ig2 (7) .
Preparation of b b-Gal Conjugates (8, n‫;2؍‬ 9, n‫)41؍‬ A b-Gal conjugate LAg1 (nϭ2) was prepared as follows: 100 ml of 4 (3.5 mg in 5 ml dioxane) with 1.0 ml of a solution of b-galactosidase (4.5 mg in 1.0 ml phosphate buffer, pH 7.3) were mixed and kept for 48 h at 4°C. The reaction mixture was applied to a column of Sepharose 6B (i.d. 1.5ϫ35 cm) and the column was eluted with buffer A to collect the fractions. Each fraction was monitored by b-galactosidase activity and tubes containing a b-Gal conjugate LAg1 (8, nϭ2) were stored under 4°C. Similarly, a mixture containing 100 ml of a solution of 5 (2.7 mg in 5 ml of dioxane) and 1.0 ml of a b-galactosidase solution (3.2 mg in 1.0 ml of phosphate buffer, pH 7.3) was kept at 4°C for 48 h. The products were purified by Sepharose 6B (i.d. 1.5ϫ35 cm) with buffer A, and stored as a b-Gal conjugate LAg2 (9, nϭ14) under 4°C.
Measurement of Numbers of the Hapten Bound to a BSA Molecule The BSA concentration was determined by the Lowry's method, 15) and the quantity of amino groups in the BSA molecule was measured by Habeeb's method. 16) Measurement of b b-Galactosidase Activity To measure b-D-galactosidase activity of b-galactosidase-labeled antigens (LAg1 and LAg2), a 1000-fold diluted solution of the labeled antigen (25 ml) was incubated with 0.1 mM 4-methylumbelliferyl b-D-galactoside (150 ml) for 30 min at 30°C and then the reaction was stopped by addition of 100 mM glycine-NaOH buffer, pH 10.3 (4 ml). The product, 4-methylumbelliferone, was spectrofluorometrically measured at wavelengths of 365 nm (excitation) and 448 nm (emission).
Preparation of Antisera (As1 and As2) to Aconitine Each 2 mg BSA conjugate dissolved (Ig1 or Ig2) in sterile saline (2 ml) was emulsified with adjuvant complete Freund (3 ml) to give an emulsion. The emulsion was administered to three rabbits by subcutaneous injection once every two weeks for three months and twice for an additional month. The entire blood volume was collected after the final injection and centrifuged at 1000ϫg for 15 min to give the respective sera As1 and As2, which were stored at Ϫ20°for EIA experiments.
EIA Procedure Samples or standard solutions containing various amounts of aconitine were incubated with an antiserum (50 ml) and 10 3 -fold diluted b-Gal conjugate (25 ml) at room temperature for 2 h. Ten fold diluted goat anti-rabbit IgG (20 ml) and 100-fold diluted normal rabbit serum (20 ml) were then added to the reaction mixture. The mixture was left overnight at 4°C. After addition of buffer A (1 ml), the resulting mixture was centrifuged at 1100ϫg for 15 min at 4°C. The supernatant was discarded, and the precipitates were washed with buffer A followed by incubation with 0.1 mM 4-methylumbelliferyl b-D-galactoside for 30 min at 30°C. The reaction was stopped by the addition of 100 mM glycine-NaOH buffer, pH 10.3 (4 ml). The fluorescence intensity of a product (4-methylumbelliferone) was spectrofluorometrically measured at wavelengths of 365 nm (excitation) and 448 nm (emission).
Sensitivity of EIA Various concentrations of aconitine (10 Ϫ2 , 10 Ϫ1 , 1, 10, 10 2 , 10 3 , 10 4 , 10 5 pg/tube) in buffer A were prepared for sensitivity determination of the EIA. The binding percentage of b-Gal conjugate antigen to antibody (B/B 0 ) was calculated to obtain a standard curve, where B 0 is the fluorescence intensity in the absence of aconitine and B is the intensity in the presence of aconitine. The concentration of aconitine showing 50% binding was obtained from the graph.
Precision of EIA (Inter-day and Intra-day Assays) The inter-day and intra-day assays were performed on the same samples to obtain a coefficient of variance (CV) under the same conditions twice at an interval of one month and twice at an interval of 16 h at 4°C, respectively.
Specificity of EIA The cross-reactivity of aconitine and related compounds at various concentrations was graphically obtained and defined as follows:
cross-reactivityϭ([aconitine]/[aconitine analogs])ϫ100%
where B/B 0 ϭ50%.
Quantitative Determination of Aconitine Levels in Plasma after Intravenous Administration to Rats
Aconitine (0.1 mg) was dissolved in DMSO (250 ml) and diluted with saline to a total volume of 5 ml. A portion of the solution was injected through the tail vein to rats at a dose of 0.02 mg aconitine/kg. The blood samples were collected through the tail vein at 5, 15 and 30 min, and then 1, 2, 4, 6 and 8 h after intravenous administration. The samples were centrifuged at 1100ϫg for 15 min to give the respective plasma samples. The plasma and 10-fold diluted plasma (5 ml) were used for EIA to determine aconitine levels. A standard calibration curve ranging from 0.1-1000 pg aconitine/tube was prepared in the presence of plasma from conventional rats.
Quantitative Determination of Aconitine Levels in Plasma after Oral Administration to Rats Aconitine (0.01 mg/ml) dissolved in DMSO-H 2 O (1 : 19) was orally administered to four rats at a dose of 0.1 mg/kg. The blood samples were repeatedly collected through the tail vein at 5, 15 and 30 min, and then 1, 2, 4, 6 and 8 h after oral administration, and centrifuged at 1100ϫg for 15 min at 4°C to give the respective plasma samples. The plasma (5 ml) was subjected to quantitative determination of aconitine by EIA.
RESULTS
Preparation of Immunogens, Enzyme-Labeled Antigens, and Anti-aconitine Antisera Dicarboxylic acid hemiesters of benzoylaconine were prepared by ester-exchanging reaction of an acetyl group at C-8 of aconitine (1) with dicarboxylic acids possessing different chain lengths, such as butanedioic acid (short chain, nϭ2) and hexadecanedioic acid (long chain, nϭ14) in the presence of collidine in THF (Fig. 1 ). These hemiesters (2, 3) were identified by 1 H-NMR, where an acetyl signal (d 1.39) at C-8 in aconitine (1) disappeared, and instead, methylene signals that originated from the dicarbonic acids appeared. The hemiesters (2, 3) of benzoylaconine were then treated with N-hydroxysuccinimide (NHS) and N,NЈ-dicyclohexyl carbodiimide (DCC) to give N-hydroxysuccinimide esters 4 and 5, respectively. The structures of the products were confirmed by the presence of a characteristic proton signal of a succinimidyl group at d H 2.85-2.86 (4H) in the 1 H-NMR spectra. The enzyme-labeled antigens were prepared by condensation of b-galactosidase with N-hydroxysuccinimide esters 4 and 5 at a molar ratio of 1 to 10 in phosphate buffer (pH 7.3). The products were purified by Sepharose 6B gel filtration. Similarly, the BSA conjugates as immunogens were prepared by coupling of BSA with N-hydroxysuccinimide esters 4 and 5 at a molar ratio of 1 to 30. The number of haptens bound to the BSA molecule was determined to be 3.0 and 4.0 in BSA conjugates 6 and 7, respectively.
By repeated subcutaneous injection of BSA conjugates 6 and 7 to rabbits, two types of antisera, Ab1 and Ab2, respectively, were obtained, and the highest binding affinity of both antisera to aconitine (1) was observed in the combination of Fig. 1 . Synthesis of Immunogens and Enzyme-Labeled Antigens from Aconitine a 10 3 fold-diluted serum Ab1 or Ab2 with a 10 3 fold-diluted solution of b-Gal conjugate 8 or 9 in the preliminary experiment. The following experiments were then carried out with these dilutions.
Construction of EIA System Satisfactory standard curves were obtained in a range of 2.5 to 25 ng aconitine/ml (0.1 pg-1 ng aconitine/tube) for the respective combinations of antisera and b-Gal-labeled antigens (Fig. 2 ). Since the concentrations of aconitine at B/B 0 ϭ50% (Table 1) were similar in all of the combinations, no significant difference in sensitivity was observed for either spacer homologous or heterologous combination between the antisera and labeled antigens.
The intra-day and inter-day assays at three different concentrations of aconitine (1, 10, 100 pg/tube) showed that the CV was in a range of 4.3-6.4% in the intra-day assay, but in a range of 4.8-28% in the inter-day assay, indicating that the inter-day assay was rather inferior with respect to reproducibility compared to the intra-day assay.
The standard curve of aconitine (1) in plasma was quite similar to that in buffer solutions in a range of 10-1000 pg/tube (data not shown), which enables us to determine the aconitine level in plasma. At aconitine concentrations of 1.0, 10 and 100 pg/tube, their CV values of variance were 2.8%, 3.1% and 2.6%, respectively, in the intra-day assay, and 0%, 15.8% and 27.4%, respectively, in the inter-day assay.
Eight aconitine-related compounds (Fig. 3) were examined in the cross reactivity experiment, which shows the relative concentrations of aconitine (1) required for 50% inhibition of binding with the antisera. The combination Ag2-Ab1 showed relatively high specificity to aconitine (1) but weak cross-reactivities to benzoylaconine, mesaconitine, and benzoylmesaconine (Table 2) , which guarantees the quantitative determination of aconitine present in samples from the body fluid. In comparison with the cross-reactivity to these compounds in the Ag2-Ab1 combination, the combination of Ag2-Ab2 showed quite high cross-reactivity against mesaconine (156.6% of aconitine), in which an ethyl group attached to the nitrogen atom in the aconitine skeleton is replaced with a methyl group. The combination of Ag2-Ab2 was not suitable for quantitative analysis of aconitine in a mixture of aconitine and mesaconitine. However, quantitative determination of each component may be possible using both combinations of Ag2-Ab1 and Ag2-Ab2.
Pharmacokinetics of Aconitine Following intravenous injection of aconitine to rats at a dose of 0.02 mg/kg, the 1292 Vol. 26, No. 9
Fig. 2. Standard Curves for Aconitine in Homologous and Heterologous Combinations between Antisera and Labeled Antigens
Bϭ% binding in the absence of aconitine, B 0 ϭ% binding in the presence of aconitine. a) Cross reactivity (%) represents a relative concentration of aconitine, which is required to induce 50% inhibition of the binding with the antisera. Fig. 3 . Structures of Aconitine and Related Compounds aconitine levels in plasma decreased rapidly within the first 1 h and then slowly (Fig. 4) . The curve seemed to fit into the two-compartment pharmacokinetic model. Table 3 shows the pharmacokinetic parameters; A, B, a, and b were obtained from straight regression lines were 56Ϯ12 ng/ml, 3.4Ϯ0.9 ng/ml, 0.049Ϯ0.007 min Ϫ1 , and 0.004Ϯ0.001 min Ϫ1 , respectively. The area under curve (AUC 0-4800 ) of 2055Ϯ294.3 ng · min/ml was obtained from a trapezoid area.
After oral administration of aconitine to rats, the plasma levels were monitored by EIA ( Fig. 5) . At a dose of 0.1 mg/kg, the aconitine levels increased rapidly and then gradually decreased 6 h after administration; the plasma level reached the maximum of 0.73Ϯ0.08 ng/ml (C max ) at 45 min after administration. On the other hand, at the higher dose of 1.0 mg/kg, the plasma level reached its peak C max (3.3Ϯ0.6 ng/ml) at 150 min and then decreased slowly. The AUC 0-1440 values were 130Ϯ4, 1600Ϯ270 ng · min/ml after administration at doses of 0.1 and 1.0 mg aconitine/kg, respectively, the ratio being 1 : 12.3 ( Table 4 ). The bioavailability (F) of orally administered aconitine was calculated to be 0.013.
DISCUSSION
Since Kitagawa et al. reported that an acetyl group at the C-8 position of aconitine was easily exchanged with a variety of fatty acids to give lipoaconitine during traditional drugprocessing, 17) and we found that aconitine was converted to lipoaconitine consisting of bacterial fatty acids by incubation with intestinal bacteria, 18) we applied this unique reaction to prepare an immunogen and an enzyme-labeled antigen for development of an EIA for aconitine. A short-chain or longchain dicarboxylic acid was introduced to an aconitine molecule as a spacer, which enables one to link aconitine as a hapten to a large molecule of protein. Then, aconitine derivatives 2 and 3 possessing short (nϭ2 in Fig. 1 ) and long chains (nϭ14) at C-8, respectively, were coupled with BSA and b-Gal through their N-hydroxysuccinimidyl ester intermediates.
Generally, a heterologous combination between an immunogen (BSA-conjugate) and an enzyme-labeled antigen (b-Gal conjugate), where a hapten and a protein are linked through different spacers in length, shows higher sensitivity and reproducibility than a homologous combination. Heikal et al. 19) reported that relatively high sensitivity was observed for the heterologous combination between the b-Gal conjugate with a short spacer and the BSA conjugate with a long spacer in their experiments with paeonimetabolin I, a major metabolite from paeoniflorin produced by intestinal bacteria. However, in the present experiment, no appreciable difference in sensitivity due to the length of spacers was observed. The aconitine concentrations determined by the respective combinations at B/B 0 50% were in a range of 2.0-3.0Ϯ 0.5-1.3 pg/tube with a small standard deviation. In the cross-reactivity experiment, the combination of Ag2-Ab1 showed relatively high specificity to aconitine. However, the combination of Ag2-Ab2 showed an extremely high cross-reactivity to mesaconitine (156.6%). It is interesting that lipoaconitine showed no appreciable cross-reactivity to aconitine with antisera Ab1 and Ab2 though these antisera had been prepared with lipoaconitine analogs.
The EIA system developed in this experiment was quite sensitive to aconitine in a range of 0.1 pg-1.0 ng, which is the most sensitive among the reported methods GC/SIM 12) and LC-frit-FAB-MS, 14) ranges of 100 pg-7.5 ng and 5-500 pg, respectively). In addition, since no pretreatment of samples from living bodies was not necessary in our EIA method, 10 ml of plasma in a range of 25 pg/ml-250 ng/ml was enough to measure it, compared with 0.5 ml of serum in a range of 200 pg/ml-15 ng/ml for the GC/SIM method and 2 ml of blood in a range of 5-50 ng/ml with the LC-frit-FAB-MS method. In this paper, the pharmacokinetics of aconitine after intravenous and oral administration to rats at low doses of 0.02 mg/kg i.v., and 0.1 and 1 mg/kg p.o., respectively, was first reported. The time course of plasma aconitine concentration after intravenous administration was well simulated by the two-compartment model, and the concentration rapidly decreased at a half life of 16 min. After oral administration, the AUC values increased proportionally to the administered dose, suggesting aconitine is readily absorbed from the rat gastrointestinal tract. However, as the late t max (150 min) and the broad peak during 5 h were observed at the high dose, it seemed to take a long time to absorb aconitine because of its low solubility in water. The systemic bioavailabilty in rats after oral administration was calculated to be extremely low (1.3%). This low bioavailability may be due to the first-pass effect. Since aconitine (1) easily changed to lipoaconitine with a variety of fatty acid residues at the C-
